28505-57-9

Basic information

• Product Name: Benzoic acid, 3,3'-methylenebis[6-hydroxy-, dimethyl ester
• CAS NO: 28505-57-9
• Molecular Formula: C17H16O6
• Molecular Weight: 316.31
• Mol File: 28505-57-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3,3'-methylenebis[6-hydroxy-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3,3'-methylenebis[6-hydroxy-, dimethyl ester(28505-57-9)
• EPA Substance Registry System: Benzoic acid, 3,3'-methylenebis[6-hydroxy-, dimethyl ester(28505-57-9)

Safety Data

• Hazardous Substances Data: 28505-57-9(Hazardous Substances Data)

Upstream product

• 69-72-7 salicylic acid 
• 50-00-0 formaldehyd 
• 119-36-8 methyl salicylate 
• 67-56-1 methanol 
• 122-25-8 5,5'-methylenedisalicylic acid 

Downstream Products

• 443687-78-3 C₃₃H₃₀Br₂O₆ 
• 327028-16-0 4,4'-bis(5-bromopentoxy)-3,3'-dicarboxymethyl-4,4'-dihydroxydiphenyl-methane 
• 122-25-8 5,5'-methylenedisalicylic acid 
• 1056452-95-9 dimethyl 5,5'-methylenebis(2-(trifluoromethylsulfonyloxy)-benzoate) 
• 1056449-47-8 dimethyl 5,5'-methylenebis(2-(3-chloro-2-methylphenylamino)benzoate) 
• 1056449-76-3 5,5'-methylenebis(2-(3-chloro-2-methylphenylamino)benzoic acid) 
• 2346-44-3 4,4'-methylenebis[2-(hydroxymethyl)phenol] 

Relevant articles and documents

Targeting MgrA-mediated virulence regulation in Staphylococcus aureus

Increasing antibiotic resistance in human pathogens necessitates the development of new approaches against infections. Targeting virulence regulation at the transcriptional level represents a promising strategy yet to be explored. A global transcriptional regulator, MgrA in Staphylococcus aureus, was identified previously as a key virulence determinant. We have performed a fluorescence anisotropy (FA)-based high-throughput screen that identified 5, 5-methylenedisalicylic acid (MDSA), which blocks the DNA binding of MgrA. MDSA represses the expression of α-toxin that is up-regulated by MgrA and activates the transcription of protein A, a gene down-regulated by MgrA. MDSA alters bacterial antibiotic susceptibilities via an MgrA-dependent pathway. A mouse model of infection indicated that MDSA could attenuate S. aureus virulence. This work is a rare demonstration of utilizing small molecules to block protein-DNA interaction, thus tuning important biological regulation at the transcriptional level.

NEW METHYLENEBISPHENYL COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein Rx, Ry, X1, X2, L1, L2, Y1 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.

Methylenedisalicylic acid derivatives: New PTP1B inhibitors that confer resistance to diet-induced obesity

Methylenedisalicylic acid derivatives were synthesized and their inhibitory activities against protein tyrosine phosphatases (PTPases) examined. Two of the compounds, 8 and 9, showed Ki values of 9.4 and 6.3 μM against PTP1B, 4- and 7-fold lower values compared to those against TC-PTP. They were reversible and slow-binding inhibitors against PTP1B. When compound 8 was fed to a mouse model, the weight gain and adipocyte fat storage induced by a high-fat-diet were significantly suppressed.